esketamine intranasal
Selected indexed studies
- Intranasal esketamine for patients with major depressive disorder: A systematic review and meta-analysis. (J Psychiatr Res, 2024) [PMID:39522447]
- Pharmacotherapy: Ketamine and Esketamine. (Psychiatr Clin North Am, 2023) [PMID:37149345]
- Intranasal esketamine: A novel drug for treatment-resistant depression. (Am J Health Syst Pharm, 2020) [PMID:32729898]
_Worker-drafted node — pending editorial review._
Connections
esketamine intranasal is a side effect of
Sources
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. (2019) pubmed
- Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis. (2024) pubmed
- Pharmacotherapy: Ketamine and Esketamine. (2023) pubmed
- Intranasal esketamine for patients with major depressive disorder: A systematic review and meta-analysis. (2024) pubmed
- Intranasal esketamine: A novel drug for treatment-resistant depression. (2020) pubmed
- Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. (2018) pubmed
- Intranasal esketamine: From origins to future implications in treatment-resistant depression. (2021) pubmed
- Intranasal Dexmedetomidine-Esketamine Combination Premedication versus Monotherapy for Reducing Emergence Delirium and Postoperative Behavioral Changes in Pediatric Tonsillectomy and/or Adenoidectomy: A Randomized Controlled Trial. (2024) pubmed
- Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. (2025) pubmed
- Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. (2018) pubmed